1 min read
Add as a preferred source on GoogleArrowhead Shares Rise After Alzheimer’s Drug Trial Data
Arrowhead Pharmaceuticals said early-stage data for ARO-MAPT led it to declare initial clinical validation of its TRiM delivery platform.
Arrowhead Pharmaceuticals shares gained more than 4% in premarket trading Wednesday, Oct. 14, after the company declared initial clinical validation of its TRiM delivery platform based on early-stage trial data for its experimental Alzheimer’s therapy, ARO-MAPT.
ARO-MAPT is an RNA interference therapy. Arrowhead’s validation statement reflects the company’s assessment of the trial data.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.